Daoyong Ni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daoyong Ni has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Chenxin Xu
School of Pharmaceutical Sciences, Wenzhou Medical University, Zhejiang, China
7 shared publications- Peng Zou
Affiliated Yueqing Hospital, Wenzhou Medical University, Zhejiang, China
7 shared publications Yinghua Chen
School of Pharmaceutical Sciences, Wenzhou Medical University, Zhejiang, China
7 shared publicationsChongchong Shu
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
6 shared publicationsWenying Fu
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, China; Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, China; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
6 shared publicationsYing Yan
Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, China; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
6 shared publications
Latest Publications
- 16 June 2026
- Published by Wiley in Advanced Synthesis & Catalysis
- Vol. 368 (12)
Iron‐Catalyzed Reaction With Carboxylic Acids and Isocyanides to Access N ‐Formylamides
Iron‐catalyzed reactions of carboxylic acids with sterically hindered isocyanides enable access to N ‐formylamides with 100% atom economy. The substrate scope can be extended to aliphatic, aromatic, and α,β‐unsaturated carboxylic acids. Furthermore, the protocol can be smoothly applied in the late‐stage N ‐formylation of acid‐containing drugs, double reaction, and N ‐formylation of alkynyl acids. A library of 41 N ‐formylamides has been constructed, and compound 4i was identified as a promising antioxidant.
- 16 June 2026
- Published by Wiley in Advanced Synthesis & Catalysis
- Vol. 368 (12)
Iron‐Catalyzed Reaction With Carboxylic Acids and Isocyanides to Access N ‐Formylamides
Iron‐catalyzed reactions of carboxylic acids with sterically hindered isocyanides enable access to N ‐formylamides with 100% atom economy. The substrate scope can be extended to aliphatic, aromatic, and α,β‐unsaturated carboxylic acids. Furthermore, the protocol can be smoothly applied in the late‐stage N ‐formylation of acid‐containing drugs, double reaction, and N ‐formylation of alkynyl acids. A library of 41 N ‐formylamides has been constructed, and compound 4i was identified as a promising antioxidant.
- 11 June 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (25) , 8148-8153
Copper-Catalyzed Domino Reaction of Isocyanides with Carboxylic Acids and PhSO 2 SeCH 3 to Access Se -CH 3 Selenocarbamates
We described a new path for the preparation of Se-CH3 selenocarbamates from readily accessible carboxylic acids, isocyanides, and PhSO2SeCH3 with the formation of new C–Se and C–N bonds. This protocol is not only suitable for late-stage derivatization of carboxylic acid drugs but also permits double reactions of three-component reactions. Most importantly, compound 4t possesses potential antioxidant activity and may alleviate oxidative stress damage by regulating the Nrf2 signaling pathway.
- 11 June 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (25) , 8148-8153
Copper-Catalyzed Domino Reaction of Isocyanides with Carboxylic Acids and PhSO 2 SeCH 3 to Access Se -CH 3 Selenocarbamates
We described a new path for the preparation of Se-CH3 selenocarbamates from readily accessible carboxylic acids, isocyanides, and PhSO2SeCH3 with the formation of new C–Se and C–N bonds. This protocol is not only suitable for late-stage derivatization of carboxylic acid drugs but also permits double reactions of three-component reactions. Most importantly, compound 4t possesses potential antioxidant activity and may alleviate oxidative stress damage by regulating the Nrf2 signaling pathway.
- 5 May 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 178, 109956
Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells
- 5 May 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 178, 109956
Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells
- 13 January 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1014, 178544
6-Methoxydihydrosanguinarine synergizes with cisplatin to enhance lung cancer cell death via ROS-mediated autophagy, ER stress, and JNK activation
- 13 January 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1014, 178544
6-Methoxydihydrosanguinarine synergizes with cisplatin to enhance lung cancer cell death via ROS-mediated autophagy, ER stress, and JNK activation
- Open Access
- 28 October 2025
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 26 (1) , 1-13
Combination of B-AP15 and HSP90 inhibitor tanespimycin induces ROS-mediated cytotoxicity in human lung cancer cells
Lung cancer continues to rank as a leading cause of cancer-related mortality worldwide. Despite notable advances in medical research, therapeutic options for advanced-stage lung cancer remain inadequate. Heat shock protein 90 (HSP90) has been identified as a potential therapeutic target in multiple malignancies, such as lung and colon cancers, owing to its pivotal role in stabilizing numerous oncoproteins. Nonetheless, the clinical application of HSP90 inhibitors has faced challenges, including suboptimal efficacy and the development of resistance mechanisms. B-AP15 is a promising small molecule in cancer therapy that functions by inhibiting deubiquitinating enzymes, which regulate protein degradation through the proteasome pathway. In this study, we aim to investigate its combinatorial activity with the HSP90 inhibitor tanespimycin (TAU) in lung cancer cells. The levels of the specified molecules were measured by Western blot analysis. Reactive oxygen species (ROS) levels were determined using the 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) probe. 53BP1 foci formation and C/EBP homologous protein (CHOP) expression were assessed by immunofluorescence. Autophagic flux was monitored using mRFP-GFP-tagged microtubule-associated protein 1 light chain 3 (LC3) lentivirus. Our findings reveal that the combination of TAU and B-AP15 induces significant synergistic antitumor effects, characterized by substantial accumulation of ROS. This ROS accumulation serves as a crucial mediator of the enhanced therapeutic response elicited by the combination treatment. Mechanistic analyses further demonstrated that the combined treatment induces cell death via activation of endoplasmic reticulum (ER) stress and the c-Jun N-terminal kinase (JNK) pathway. In summary, our study provides robust evidence supporting the potential of combining TAU with B-AP15 as a viable therapeutic option for lung cancer treatment.
- 28 October 2025
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 26 (1) , 1-13
Open AccessCombination of B-AP15 and HSP90 inhibitor tanespimycin induces ROS-mediated cytotoxicity in human lung cancer cells
Lung cancer continues to rank as a leading cause of cancer-related mortality worldwide. Despite notable advances in medical research, therapeutic options for advanced-stage lung cancer remain inadequate. Heat shock protein 90 (HSP90) has been identified as a potential therapeutic target in multiple malignancies, such as lung and colon cancers, owing to its pivotal role in stabilizing numerous oncoproteins. Nonetheless, the clinical application of HSP90 inhibitors has faced challenges, including suboptimal efficacy and the development of resistance mechanisms. B-AP15 is a promising small molecule in cancer therapy that functions by inhibiting deubiquitinating enzymes, which regulate protein degradation through the proteasome pathway. In this study, we aim to investigate its combinatorial activity with the HSP90 inhibitor tanespimycin (TAU) in lung cancer cells. The levels of the specified molecules were measured by Western blot analysis. Reactive oxygen species (ROS) levels were determined using the 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) probe. 53BP1 foci formation and C/EBP homologous protein (CHOP) expression were assessed by immunofluorescence. Autophagic flux was monitored using mRFP-GFP-tagged microtubule-associated protein 1 light chain 3 (LC3) lentivirus. Our findings reveal that the combination of TAU and B-AP15 induces significant synergistic antitumor effects, characterized by substantial accumulation of ROS. This ROS accumulation serves as a crucial mediator of the enhanced therapeutic response elicited by the combination treatment. Mechanistic analyses further demonstrated that the combined treatment induces cell death via activation of endoplasmic reticulum (ER) stress and the c-Jun N-terminal kinase (JNK) pathway. In summary, our study provides robust evidence supporting the potential of combining TAU with B-AP15 as a viable therapeutic option for lung cancer treatment.
- 23 October 2025
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 506, 117606
The glutamyl-prolyl-tRNA synthetase 1 inhibitor halofuginone exerts synergistic antitumor effects with bortezomib in colon cancer cells
- 23 October 2025
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 506, 117606
The glutamyl-prolyl-tRNA synthetase 1 inhibitor halofuginone exerts synergistic antitumor effects with bortezomib in colon cancer cells
- 9 October 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (42) , 11843-11847
Cobalt-Catalyzed Methylselenation of Boronic Reagents with PhSO 2 SeCH 3
A bench-stable, easy-to-handle, and feasible scalable methylselenating reagent PhSO2SeCH3 was designed and prepared. An array of aryl boronic reagents could undergo electrophilic methylselenation with PhSO2SeCH3 in the presence of CoCl2 and 1,10-Phen to access functionalized arylmethyl selenides, which have important applications in the discovery of antineoplastic drugs. The powerful synthetic applications were demonstrated in late-stage methylselenation of bioactive molecules, 2-fold methylselenation of aryl boronic acids, trideuteromethylselenation and derivative modification of the product.
- 9 October 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (42) , 11843-11847
Cobalt-Catalyzed Methylselenation of Boronic Reagents with PhSO 2 SeCH 3
A bench-stable, easy-to-handle, and feasible scalable methylselenating reagent PhSO2SeCH3 was designed and prepared. An array of aryl boronic reagents could undergo electrophilic methylselenation with PhSO2SeCH3 in the presence of CoCl2 and 1,10-Phen to access functionalized arylmethyl selenides, which have important applications in the discovery of antineoplastic drugs. The powerful synthetic applications were demonstrated in late-stage methylselenation of bioactive molecules, 2-fold methylselenation of aryl boronic acids, trideuteromethylselenation and derivative modification of the product.
- Open Access
- 9 September 2025
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 58 (4) , 1332-1354
Synergistic Anticancer Effects of Lenvatinib and Celastrol via ROS-Mediated ER Stress and JNK Signaling in Colon Cancer Cells
Synergistic Anticancer Effects of Lenvatinib and Celastrol via ROS-Mediated ER Stress and JNK Signaling in Colon Cancer Cells
- 9 September 2025
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 58 (4) , 1332-1354
Open AccessSynergistic Anticancer Effects of Lenvatinib and Celastrol via ROS-Mediated ER Stress and JNK Signaling in Colon Cancer Cells
Synergistic Anticancer Effects of Lenvatinib and Celastrol via ROS-Mediated ER Stress and JNK Signaling in Colon Cancer Cells
- Open Access
- 1 August 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-16
Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer
Adagrasib, a KRASG12C inhibitor, recently received accelerated approval from the US FDA for the treatment of patients diagnosed with KRASG12C-mutated non-small cell lung cancer. Although adagrasib has demonstrated excellent clinical efficacy and good safety, the molecular mechanism underlying the antitumor activity of adagrasib remains elusive. Here, we report that adagrasib treatment markedly inhibited the growth of cells harboring the KRASG12C mutation, whereas the non-KRASG12C cell lines H1299 and PC-9 were also sensitive to adagrasib, indicating that adagrasib exerted off-target effects. Mechanism studies indicated that adagrasib treatment reduced the level of NRF2 via upregulating its ubiquitination, and NRF2 overexpression can reverse the adagrasib-induced cell death in H23 and H1299 cells. Furthermore, adagrasib treatment significantly increased the cellular ROS level and thereby activating autophagy and AKT signaling pathways in H23 and H1299 cells. Importantly, combination of adagrasib with panobinostat demonstrated enhanced antitumor activity in vitro and in vivo. Overall, our data elucidate a novel mechanism of adagrasib, which will be critical for the clinical application of adagrasib.
- 1 August 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-16
Open AccessPanobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer
Adagrasib, a KRASG12C inhibitor, recently received accelerated approval from the US FDA for the treatment of patients diagnosed with KRASG12C-mutated non-small cell lung cancer. Although adagrasib has demonstrated excellent clinical efficacy and good safety, the molecular mechanism underlying the antitumor activity of adagrasib remains elusive. Here, we report that adagrasib treatment markedly inhibited the growth of cells harboring the KRASG12C mutation, whereas the non-KRASG12C cell lines H1299 and PC-9 were also sensitive to adagrasib, indicating that adagrasib exerted off-target effects. Mechanism studies indicated that adagrasib treatment reduced the level of NRF2 via upregulating its ubiquitination, and NRF2 overexpression can reverse the adagrasib-induced cell death in H23 and H1299 cells. Furthermore, adagrasib treatment significantly increased the cellular ROS level and thereby activating autophagy and AKT signaling pathways in H23 and H1299 cells. Importantly, combination of adagrasib with panobinostat demonstrated enhanced antitumor activity in vitro and in vivo. Overall, our data elucidate a novel mechanism of adagrasib, which will be critical for the clinical application of adagrasib.
- Open Access
- 15 October 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (43) , 43697-43705
ML385, an Nrf2 Inhibitor, Synergically Enhanced Celastrol Triggered Endoplasmic Reticulum Stress in Lung Cancer Cells
Lung cancer is one of the leading causes of death. Celastrol is a natural product that has shown anticancer activity but has not yet been applied in clinical settings due to its narrow therapeutic window. In this study, we discovered that celastrol stimulates an abnormal rise in the reactive oxygen species (ROS) level in lung cancer cells and that the ROS scavenger N-acetylcysteine (NAC) could counteract the cell death caused by celastrol. At the same time, celastrol upregulated the expression of cytoprotective transcription factor Nrf2 and its downstream proteins, which are effective in preventing the oxidative damage caused by ROS accumulation. Notably, we found that the overexpression of Nrf2 enhances the tolerance of lung cancer cells to celastrol and that lung cancer cells H460 with a Keap1 mutation are insensitive to celastrol. This indicates that the increase in Nrf2 contributes to the survival of lung cancer cells. Thus, we brought in an Nrf2 inhibitor ML385 to suppress the activation of Nrf2. We found that when ML385 and celastrol were added together the survival rates of lung cancer cells decreased more and the detected ROS level became much higher compared to treatment with celastrol alone. We also discovered that ML385 suppressed the expression of HO-1 and GCLC, which amplified celastrol-induced ATF4/CHOP-dependent endoplasmic reticulum stress (ER stress). Above all, our study found that ML385 enhanced celastrol-induced increases in ROS and ER stress, leading to lung cancer cell death. This research provides a potential strategy for the preclinical investigation of celastrol.
- 15 October 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (43) , 43697-43705
Open AccessML385, an Nrf2 Inhibitor, Synergically Enhanced Celastrol Triggered Endoplasmic Reticulum Stress in Lung Cancer Cells
Lung cancer is one of the leading causes of death. Celastrol is a natural product that has shown anticancer activity but has not yet been applied in clinical settings due to its narrow therapeutic window. In this study, we discovered that celastrol stimulates an abnormal rise in the reactive oxygen species (ROS) level in lung cancer cells and that the ROS scavenger N-acetylcysteine (NAC) could counteract the cell death caused by celastrol. At the same time, celastrol upregulated the expression of cytoprotective transcription factor Nrf2 and its downstream proteins, which are effective in preventing the oxidative damage caused by ROS accumulation. Notably, we found that the overexpression of Nrf2 enhances the tolerance of lung cancer cells to celastrol and that lung cancer cells H460 with a Keap1 mutation are insensitive to celastrol. This indicates that the increase in Nrf2 contributes to the survival of lung cancer cells. Thus, we brought in an Nrf2 inhibitor ML385 to suppress the activation of Nrf2. We found that when ML385 and celastrol were added together the survival rates of lung cancer cells decreased more and the detected ROS level became much higher compared to treatment with celastrol alone. We also discovered that ML385 suppressed the expression of HO-1 and GCLC, which amplified celastrol-induced ATF4/CHOP-dependent endoplasmic reticulum stress (ER stress). Above all, our study found that ML385 enhanced celastrol-induced increases in ROS and ER stress, leading to lung cancer cell death. This research provides a potential strategy for the preclinical investigation of celastrol.